This product is diluted and in a ready-to-use formulation.
A recommended positive control tissue for this product is Epithelial Sarcoma, however positive controls are not limited to this tissue type.
The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.
The INI-1 gene (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1) is a protein that in humans is encoded by the SMARCB1 gene. The protein encoded by this gene is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. This gene has been found to be a tumor suppressor, which is often mutated or deleted in malignant rhabdoid tumors, epithelioid sarcoma, and some malignant peripheral nerve sheath (MPNST) tumors.
Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.
A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.
Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.
The SWI-SNF complex is involved in the activation of transcription via the remodeling of nucleosome structure in an ATP-dependent manner. Brm (also designated SNF2alpha) and Brg-1 (also designated SNF2beta) are the ATPase subunits of the mammalian SWI-SNF complex. Brm, Brg-1, Ini1 (integrase interactor 1, also designated SNF5), BAF155 (also designated SRG3) and BAF170 are thought to comprise the functional core of the SWI-SNF complex. Addition of Ini1, BAF155 and BAF170 to Brg-1 appears to increase remodeling activity. Other complex subunits are thought to play regulatory roles. hSNF2L and hSNF2H both appear to be homologs of Drosophila ISWI, a Brm related ATPase that is present in chromatin remodeling complexes other than SWI/SNF, including the NURF (nucleosome remodeling factor).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: BAF47; BRG1-associated factor 47; BRG1-associated factor 47 (BAF47); hSNF5; Integrase interactor 1 protein; malignant rhabdoid tumor suppressor; protein phosphatase 1, regulatory subunit 144; SNF5 homolog; Sucrose nonfermenting yeast homolog like 1; sucrose nonfermenting, yeast, homolog-like 1; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1; SWI/SNF-related matrix-associated protein; SWI10; TYE4
Gene Aliases: BAF47; CSS3; hSNFS; INI1; MRD15; PPP1R144; RDT; RTPS1; Sfh1p; SMARCB1; SNF5; SNF5L1; Snr1; SWNTS1
UniProt ID: (Human) Q12824
Entrez Gene ID: (Human) 6598